TR3 modulates platinum resistance in ovarian cancer

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4758-4769

  Wilson, Andrew J ^a   Liu, Annie Y ^a   Roland, Joseph ^a   Adebayo, Oluwafunmilayo B ^a   Fletcher, Sarah A ^a   Slaughter, James C ^a   Saskowski, Jeanette ^a   Crispens, Marta A ^a,b   Jones III, Howard W ^a,b   James, Samuel ^a   Fadare, Oluwole ^a,b   Khabele, Dineo ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN 60; CISPLATIN; CYTOCHROME C; DOXORUBICIN; NUCLEAR RECEPTOR NUR77; PROTEIN KINASE B; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; VORINOSTAT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROTEIN TRANSPORT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881407326     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4560     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008;26:995-1005.
3. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
4. Lee SO, Li X,Khan S, Safe S. TargetingNR4A1 (TR3) in cancer cells and tumors. Expert Opin Ther Targets 2011;15:195-206.
5. Sibayama-Imazu T, Fujisawa Y, Masuda Y, Aiuchi T, Nakajo S, Itabe H, et al. Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei. J Cancer Res Clin Oncol 2008;134:803-12.
6. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000;289:1159-64.
7. Wilson AJ, Arango D, Mariadason JM, Heerdt BG, Augenlicht LH. TR3/Nur77 in colon cancer cell apoptosis. Cancer Res 2003;63: 5401-7.
8. Zhan Y, Du X, Chen H, Liu J, Zhao B, Huang D, et al. Cytosporone B is an agonist for nuclear orphan receptor Nur77. Nat Chem Biol 2008; 4:548-56.
9. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004;116:527-40.
10. Yu H, Kumar SM, Fang D, Acs G, Xu X. Nuclear orphan receptor TR3/ Nur77 mediates melanoma cell apoptosis. Cancer Biol Ther 2007;6: 405-12.
11. Wu Q, Liu S, Ye XF, Huang ZW, Su WJ. Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells. Carcinogenesis 2002;23:1583-92.
12. Shin HJ, Lee BH, Yeo MG, Oh SH, Park JD, Park KK, et al. Induction of orphan nuclear receptor Nur77 gene expression and its role in cadmium- induced apoptosis in lung. Carcinogenesis 2004;25:1467-75.
13. Yoon K, Lee SO, Cho SD, Kim K, Khan S, Safe S. Activation of nuclear TR3 (NR4A1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors. Carcinogenesis 2011;32:836-42.
14. Yao LM, He JP, Chen HZ, Wang Y, Wang WJ, Wu R, et al. Orphan receptor TR3 participates in cisplatin-induced apoptosis via Chk2 phosphorylation to repress intestinal tumorigenesis. Carcinogenesis 2012;33:301-11.
15. Han YH, Cao X, Lin B, Lin F, Kolluri SK, Stebbins J, et al. Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 2006;25:2974-86.
16. Cho SD, Yoon K, Chintharlapalli S, Abdelrahim M, Lei P, Hamilton S, et al. Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways. Cancer Res 2007;67:674-83.
17. Alexopoulou AN, Leao M, Caballero OL, Da Silva L, Reid L, Lakhani SR, et al. Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res 2010;12:R51.
18. Moll UM, Marchenko N, Zhang XK. p53 and Nur77/TR3-transcription factors that directly target mitochondria for cell death induction. Oncogene 2006;25:4725-43.
19. Fahrner TJ, Carroll SL, Milbrandt J. The NGFI-B protein, an inducible member of the thyroid/steroid receptor family, is rapidly modified posttranslationally. Mol Cell Biol 1990;10:6454-9.
20. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33: 49-54.
21. Chen HZ, Liu QF, Li L, Wang WJ, Yao LM, Yang M, et al. The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating Wnt signalling. Gut 2012;61:714-24.
22. Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, et al. DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther 2009;8:713-24.
23. Scudiero DA, Monks A, Sausville EA. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 1998;90:862.
24. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12.
25. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther 2007;6:795-801.
26. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, et al. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 2010;9:2377-88.
27. Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, et al. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther 2011;12:484-93.
28. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 2008;19:4062-75.
29. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-812.
30. Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol Oncol 2012;127:579-86.
31. Denny L, Quinn M, Hacker N. FIGO Cancer Report 2012. Int J Gynaecol Obstet 2012;119 Suppl 2:S89.
32. Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, et al. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Int J Clin Exp Pathol 2012;5:37-45.
33. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS ONE 2010;5:e9615.
34. Li F, Meng L, Zhou J, Xing H, Wang S, Xu G, et al. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1. Biochem Biophys Res Commun 2005;335:1070-7.
35. Shin M, Yan C, Boyd D. An inhibitor of c-JUN aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 2002;1589:311-6.
36. Hazzalin CA, Le Panse R, Cano E, Mahadevan LC. Anisomycin selectively desensitizes signalling components involved in stress kinase activation andFOSand JUN induction. Mol Cell Biol 1998;18:1844-54.
37. Whitley BR, Beaulieu LM, Carter JC, Church FC. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007;104:470-9.
38. Lei P, Abdelrahim M, Cho SD, Liu X, Safe S. Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(30-indoly)-1-(p-substituted phenyl) methanes. Mol Cancer Ther 2008;7:3363-72.
39. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6.
40. Chock KL, Allison JM, Shimizu Y, ElShamy WM. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 2010;70:8782-91.
41. Ali AY, Abedini MR, Tsang BK. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 2012;31: 2175-86.
42. Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, et al. BADphosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 2011;17:6356-66.
43. Wang Y, Mao H, Hao Q, Yang Y, Shen L, Huang S, et al. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer. Regul Pept 2012;178: 36-42.
44. Zhang P, Liu SS, Ngan HY. TAp73-mediated the activation of c-Jun Nterminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS ONE 2012;7:e42985.